A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation

European Respiratory Journal

Volumn 45, Issue 2, 2015, Pages 541-544

  Middleton, Anna ^a,b   Robinson, Paul D ^a,b   McKay, Karen ^a,b   Jaffe, Adam ^c,d   Selvadurai, Hiran ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MANNITOL; POWDER;

ANTIBIOTIC THERAPY; BLOOD CARBON DIOXIDE TENSION; BLURRED VISION; BREATH ANALYSIS; CARDIOPULMONARY EXERCISE TEST; CHILD; CHILD CARE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED PULMONARY EXACERBATION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRY POWDER; FEASIBILITY STUDY; FORCED EXPIRATORY VOLUME; HEADACHE; HEMOPTYSIS; HOSPITAL CARE; HUMAN; LETTER; LOW DRUG DOSE; LUNG CLEARANCE; LUNG DISEASE; LUNG MINUTE VOLUME; LUNG VENTILATION; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PILOT STUDY; PLETHYSMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; SPIROMETRY; TREADMILL EXERCISE; TREATMENT DURATION; VOMITING; ADMINISTRATION AND DOSAGE; COMPLICATION; DRY POWDER INHALER; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; LUNG FUNCTION TEST; POWDER; SAMPLE SIZE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; DRY POWDER INHALERS; HUMANS; LUNG DISEASES; MANNITOL; OXYGEN CONSUMPTION; PILOT PROJECTS; POWDERS; RESPIRATORY FUNCTION TESTS; SAMPLE SIZE; SPIROMETRY; TREATMENT OUTCOME;

EID: 84961348514     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00137814     Document Type: Letter

References (15)

1. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-632.
2. Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Op Pulm Med 2011;17:442-447.
3. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185:645-652.
4. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-642.
5. Daviskas E, Anderson SD, Brannan JD, et al. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 1997;10:2449-2454.
6. Daviskas E, Anderson SD, Jaques A, et al. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2010;137:861-868.
7. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133:1388-1396.
8. Kanga J, Kuhn R, Craigmyle L, et al. Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation. Clin Ther 1999;21:1343-1356.
9. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-1618.
10. Robinson PD, Cooper P, Van Asperen P, et al. Using index of ventilation to assess response to treatment for acute pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2009;44:733-742.
11. Robinson PD, Turner M, Brown NJ, et al. Procedures to improve the repeatability of forced oscillation measurements in school-aged children. Respir Physiol Neurobiol 2011;177:199-206.
12. American Thoracic Society, European Respiratory SocietyATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med 2005;172:1463-1471.
13. Hall GL, Stanojevic S, Beasley R, et al. Revised historical spirometry reference ranges are reflective of contemporary healthy spirometry values. Eur Respir J 2008;32 Suppl. 52:382s-383s.
14. Subbarao P, Stanojevic S, Brown M, et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis: a pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med 2013;188:456-460.
15. Daviskas E, Anderson SD, Eberl S, et al. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001;119:414-421.